DALLAS, June 01, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that management will present a company overview at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 9:30 a.m. ET.
A live webcast of the presentation may be accessed at: https://wsw.com/webcast/jeff174/til/1707183 or by visiting the News & Events section of the Instil Bio website at www.instilbio.com . An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.
About Instil Bio
Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. Instil has assembled an accomplished management team with a successful track record in the development, manufacture, and commercialization of cell therapies. Using the company’s proprietary, optimized, and scalable manufacturing processes at its in-house manufacturing facilities, Instil is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma and other solid tumors as well as ITIL-306, a next-generation, genetically engineered TIL therapy for multiple solid tumors. For more information visit www.instilbio.com and LinkedIn.
Contacts:
Investor Relations 1-972-499-3350 investor.relations@instilbio.com www.instilbio.com Brendan Payne Stern Investor Relations 1-212-362-1200 brendan.payne@sternir.com |